Why the study?
What are the clinical and genetic determinants of high on-treatment platelet reactivity to clopidogrel in Puerto Rican patients with cardiovascular disease?
What are the clinical and genetic determinants of high on-treatment platelet reactivity to clopidogrel in Puerto Rican patients with cardiovascular disease?
A predictive model incorporating clinical and genetic variables can determine platelet reactivity to identify Puerto Rican Hispanic patients at higher risk for adverse events on clopidogrel.
Answers are grounded in this paper and cite their sources.
May help stratify HTPR risk in Puerto Rican patients on clopidogrel; leaves open validation before guiding therapy.
INTRODUCTION: High on-treatment platelet reactivity (HTPR) to clopidogrel imparts an increased risk for ischemic events in adults with coronary artery disease. Platelet reactivity varies with ethnicity and is influenced by both clinical and genetic variables; however, no clopidogrel pharmacogenetic studies with Puerto Rican patients have been reported. Therefore, we sought to identify clinical and genetic determinants of on-treatment platelet reactivity in a cohort of Puerto Rican patients with cardiovascular disease. METHODS: Genotyping Assays. RESULTS: (OR=4.44; 95% CI: 1.21-16.20) were the only independent predictors of HTPR. CONCLUSION: Moreover, we propose a predictive model to determine PRU values as measured by VerifyNow P2Y12 assay for the Puerto Rican Hispanic population. This model has the potential to identify Hispanic patients at higher risk for adverse events on clopidogrel.
No takes yet. Share an insight, caveat, or question.
Hernández-Suárez et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: